After a huge two week really, is Tuesday's market weakness an early sign of a sharp pull back or nothing more than expected profit taking?
So far this quarter, only one S&P healthcare company, Aetna, has missed its consensus EPS estimate. This week there are over 20 more healthcare companies reporting. Yesterday after the bell Amgen blew the cover off the ball with a 40% rise in earnings and this morning, Teva Pharmaceuticals beat by three cents per share.
Stock futures drifted slightly lower ahead of the open Tuesday as investors waited for the next batch of earnings and key economic data.
In the final minutes of trading the bulls foiled the bears and sent both the S&P 500 and Dow higher as investors rotated into financials...
Stocks eked out a gain Monday as banks got a boost from a jump in new-home sales. Stocks had struggled for much of the day as investors worried about a a record $200 billion in Treasury auctions this week and lowered outlooks from Honeywell and Aetna cast a shadow over the market.
The Dow poked into positive territory Monday afternoon, led by Bank of America, as a jump in new-home sales buoyed bank stocks. Still, the blue-chip index struggled to stay above water as worries about a record $200 billion in Treasury auctions this week and lowered outlooks from Honeywell and Aetna cast a shadow over the market.
With nearly 150 more companies due to flood the Street with earnings the bulls appear to be getting a little tired. Is this the pause that refreshes or are investors growing concerned?
Opposition to the Obama administration's health care plan had a new voice Monday, as the U.S. Chamber of Commerce launched a critical ad campaign suggesting alternatives. But John Sullivan of Leerink Swann says this is a great time to buy health stocks.
Stocks got a quick pop Monday after a sharp jump in new home sales, but quickly resumed their decline as lowered outlooks from Honeywell and Aetna cast a shadow over the market.
Stock index futures edged higher ahead of the open Monday as investors look to see if the summer rally will keep pushing the major indexes higher.
There is no doubt that something has to be done about the rising cost of health care in the United States. The status quo is a recipe for disaster and, considering the gigantic federal deficit, the last thing the United States needs is an even larger anchor on fiscal health.
Drug maker Wyeth, in the process of being acquired by Pfizer, reported a quarterly profit that was better than analysts predicted and also raised its full-year earnings guidance.
A bitter Congressional fight over the cost of superexpensive biotechnology drugs has come down to a single, hotly debated number: How many years should makers of those drugs be exempt from generic competition?
Our traders are good but you knew that! Check out their latest picks that paid in a regular feature we call "Quicker Than The Ticker."
Following are the week’s biggest winners and losers. Find out why shares of Amgen and American Express popped while NYSE and Microsoft dropped.
On a week where GM emerged from bankruptcy protection, oil settled below $60 per barrel, and earnings season had its unofficial kick off with Alcoa, the US markets extended their losing streak to 4 straight weeks.
With Amgen generating a new and potential blockbuster drug, should you try to get in on the action?
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
A late upturn pushed stocks higher Wednesday as investors rotated into defensive stocks like pharmaceuticals and Alcoa advanced ahead of earnings.
Stocks turned lower Wednesday as investors got defensive ahead of earnings season, rotating into pharmaceuticals and out of techs.